| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Galecto Inc. | GB0139 - (GALACTIC-1) | Idiopathic pulmonary fibrosis (IPF) | Phase 2b | Trial Discontinued | Inhalation | Respiratory |
| Galecto Inc. | GB2064 - (MYLOX-1) | Myelofibrosis | Phase 2a | Data Released | Oral | Hematology |
| Galecto Inc. | GB1211 in combination with Tecentriq (atezolizumabe) - (GALLANT-1) | Non-small cell lung cancer (NSCLC) | Phase 2a | Trial Completed | Intravenous | Oncology |
| Galecto Inc. | GB1211 in combination with KEYTRUDA (pembrolizumab) | Melanoma and head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Ongoing | GB1211 is administered orally and KEYTRUDA is administered intravenously | Oncology |
| Galecto Inc. | GB1211 in combination with Tecentriq (atezolizumabe) - (GALLANT-1) | Non-small cell lung cancer (NSCLC) | Phase 2a | Trial Completed | Intravenous | Oncology |
| Galecto Inc. | GB0139 | COVID-19 | Phase 2 | Trial Discontinued | Inhalation | COVID-19 |
| Galera Therapeutics Inc. | Rucosopasem (GC4711) - (GRECO-2) | Pancreatic Cancer | Phase 2b | Trial Discontinued | Intravenous | Oncology |
| Galmed Pharmaceuticals Ltd. | Aramchol - ARRIVE | HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD) | Phase 2 | Oral | Anti-HIV |